PLOS has joined a list of endorsers of the Position Statement on Open Access coordinated by Open Pharma, a group of pharmaceutical clients, publishers, patients, academics, regulators, editors, non-pharmaceutical funders, and societies.
PLOS is a fully Open Access publisher, with all content published with a CC-BY license. PLOS is therefore ready to support the aims of Open Pharma without delay or need to alter policies. It supports any and all moves to open science, and to improve the integrity of research.
The pharmaceutical industry funds roughly half of all biomedical research, yet has been slower to adopt the Open Access and Open Science policies that are now becoming mainstream. By endorsing this position statement, PLOS ensures the pharmaceutical industry understands it is just as welcome and able to submit to PLOS journals as any other research group. Robust editorial policies, open data policy, and Open Science mission of PLOS will help the industry validate and demonstrate the credibility of its work.
Brought to you by Scope e-Knowledge Center, a trusted global partner for digital content transformation solutions - Abstracting & Indexing (A&I), Knowledge Modeling (Taxonomies, Thesauri and Ontologies), and Metadata Enrichment & Entity Extraction.
Click here to read the original press release.
